Difference between revisions of "Vindesine (Eldisine)"
Jump to navigation
Jump to search
(updated also known as) |
m |
||
| (27 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
| − | + | ''Not approved by the FDA. Approved for use in some countries e.g., U.K., South Africa.'' | |
==General information== | ==General information== | ||
| − | Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.<ref name="insert">[http://www.bccancer.bc.ca/NR/rdonlyres/D6279B9B-2F71-4784-8AF8-D1452648635C/19507/Vindesinemonograph_3Nov07.pdf Vindesine (Eldisine) package insert]</ref><ref>[[ | + | Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.<ref name="insert">[http://www.bccancer.bc.ca/NR/rdonlyres/D6279B9B-2F71-4784-8AF8-D1452648635C/19507/Vindesinemonograph_3Nov07.pdf Vindesine (Eldisine) package insert]</ref><ref>[[:File:Vindesine.pdf | Vindesine (Eldisine) package insert (locally hosted backup)]]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[vesicant]] | <br>Extravasation: [[vesicant]] | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Non- | + | *[[Adult T-cell leukemia-lymphoma]] |
| + | *[[Burkitt lymphoma]] | ||
| + | *[[CNS lymphoma]] | ||
| + | *[[Diffuse large B-cell lymphoma]] | ||
| + | *[[HIV-associated lymphoma]] | ||
| + | *[[Melanoma]] | ||
| + | *[[Neuroblastoma]] | ||
| + | *[[Non-small cell lung cancer]] | ||
| + | *[[Post-transplant lymphoproliferative disorder]] | ||
| + | |||
| + | ==Diseases for which it was used== | ||
| + | *[[Acute myeloid leukemia - historical|Acute myeloid leukemia]] | ||
| + | *[[Small cell lung cancer - historical|Small cell lung cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 15: | Line 27: | ||
*[http://www.genuspharma.com/assets/Vindesine-PIL.pdf Vindesine (Eldisine) patient information at Genus Pharmaceuticals]<ref>[http://www.genuspharma.com/assets/Vindesine-PIL.pdf Vindesine (Eldisine) patient information at Genus Pharmaceuticals]</ref> | *[http://www.genuspharma.com/assets/Vindesine-PIL.pdf Vindesine (Eldisine) patient information at Genus Pharmaceuticals]<ref>[http://www.genuspharma.com/assets/Vindesine-PIL.pdf Vindesine (Eldisine) patient information at Genus Pharmaceuticals]</ref> | ||
*[http://www.uptodate.com/contents/vindesine-patient-drug-information Vindesine (Eldisine) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/vindesine-patient-drug-information Vindesine (Eldisine) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/vindesine-patient-drug-information Vindesine (Eldisine) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/vindesine-patient-drug-information Vindesine (Eldisine) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | *1979-04-11: EURD | ||
| + | ==Also known as== | ||
| + | *'''Code name:''' LY-099094 | ||
| + | *'''Generic names:''' desacetylvinblastine amide, DAVA, DVA, VDS | ||
| + | *'''Brand names:''' Eldesine, Eldisin, Eldisine, Enison, Fildesin, Gesidine | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Intravenous medications]] | ||
| + | [[Category:Vesicant]] | ||
| + | |||
| + | [[Category:Microtubule inhibitors]] | ||
| + | [[Category:Vinca alkaloids]] | ||
| + | |||
| + | [[Category:Adult T-cell leukemia-lymphoma medications]] | ||
| + | [[Category:Burkitt lymphoma medications]] | ||
| + | [[Category:CNS lymphoma medications]] | ||
| + | [[Category:Diffuse large B-cell lymphoma medications]] | ||
| + | [[Category:HIV-associated lymphoma medications]] | ||
| + | [[Category:Melanoma medications]] | ||
| + | [[Category:Neuroblastoma medications]] | ||
| + | [[Category:Non-small cell lung cancer medications]] | ||
| + | [[Category:Post-transplant lymphoproliferative disorder medications]] | ||
| + | |||
| + | [[Category:Acute myeloid leukemia medications (historic)]] | ||
| + | [[Category:Small cell lung cancer medications (historic)]] | ||
| + | |||
| + | [[Category:EMA approved in 1979]] | ||
Revision as of 00:22, 7 November 2023
Not approved by the FDA. Approved for use in some countries e.g., U.K., South Africa.
General information
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adult T-cell leukemia-lymphoma
- Burkitt lymphoma
- CNS lymphoma
- Diffuse large B-cell lymphoma
- HIV-associated lymphoma
- Melanoma
- Neuroblastoma
- Non-small cell lung cancer
- Post-transplant lymphoproliferative disorder
Diseases for which it was used
Patient drug information
- Vindesine (Eldisine) patient information at Macmillan Cancer Support[3]
- Vindesine (Eldisine) patient information at Genus Pharmaceuticals[4]
- Vindesine (Eldisine) patient drug information (UpToDate)[5]
History of changes in EMA indication
- 1979-04-11: EURD
Also known as
- Code name: LY-099094
- Generic names: desacetylvinblastine amide, DAVA, DVA, VDS
- Brand names: Eldesine, Eldisin, Eldisine, Enison, Fildesin, Gesidine
References
- ↑ 1.0 1.1 Vindesine (Eldisine) package insert
- ↑ Vindesine (Eldisine) package insert (locally hosted backup)
- ↑ Vindesine (Eldisine) patient information at Macmillan Cancer Support
- ↑ Vindesine (Eldisine) patient information at Genus Pharmaceuticals
- ↑ Vindesine (Eldisine) patient drug information (UpToDate)
Categories:
- Drugs
- Intravenous medications
- Vesicant
- Microtubule inhibitors
- Vinca alkaloids
- Adult T-cell leukemia-lymphoma medications
- Burkitt lymphoma medications
- CNS lymphoma medications
- Diffuse large B-cell lymphoma medications
- HIV-associated lymphoma medications
- Melanoma medications
- Neuroblastoma medications
- Non-small cell lung cancer medications
- Post-transplant lymphoproliferative disorder medications
- Acute myeloid leukemia medications (historic)
- Small cell lung cancer medications (historic)
- EMA approved in 1979